MX355041B - Dominios de union a albumina consenso no naturales. - Google Patents

Dominios de union a albumina consenso no naturales.

Info

Publication number
MX355041B
MX355041B MX2014014384A MX2014014384A MX355041B MX 355041 B MX355041 B MX 355041B MX 2014014384 A MX2014014384 A MX 2014014384A MX 2014014384 A MX2014014384 A MX 2014014384A MX 355041 B MX355041 B MX 355041B
Authority
MX
Mexico
Prior art keywords
binding domains
albumin binding
natural consensus
consensus albumin
natural
Prior art date
Application number
MX2014014384A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014384A (es
Inventor
Steven Jacobs
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2014014384A publication Critical patent/MX2014014384A/es
Publication of MX355041B publication Critical patent/MX355041B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2014014384A 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales. MX355041B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US201361776918P 2013-03-12 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
MX2014014384A MX2014014384A (es) 2015-05-11
MX355041B true MX355041B (es) 2018-03-28

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014384A MX355041B (es) 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales.

Country Status (15)

Country Link
US (3) US9156887B2 (https=)
EP (1) EP2855509B1 (https=)
JP (3) JP2015519345A (https=)
KR (1) KR102053674B1 (https=)
CN (1) CN104470944B (https=)
AU (2) AU2013266215B2 (https=)
BR (1) BR112014029409B1 (https=)
CA (1) CA2874646C (https=)
DK (1) DK2855509T3 (https=)
EA (1) EA036487B1 (https=)
ES (1) ES2670442T3 (https=)
IL (2) IL235808A (https=)
MX (1) MX355041B (https=)
PT (1) PT2855509T (https=)
WO (1) WO2013177398A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
WO2014140882A2 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
JP2018518945A (ja) * 2015-04-29 2018-07-19 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 可溶性キメラインターロイキン−10受容体およびその療法使用
US10456442B2 (en) * 2015-06-18 2019-10-29 Albert Einstein College Of Medicine FGF receptor ligands for treating diabetes and obesity
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
CA3054286A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018140456A1 (en) 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
JP7744621B2 (ja) 2017-08-11 2025-09-26 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115175691B (zh) 2019-12-18 2026-02-10 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用
US12123036B2 (en) 2020-02-26 2024-10-22 Northwestern University Soluble ACE2 variants and uses therefor
US20240293487A1 (en) * 2020-03-25 2024-09-05 Jin-Woo Choi Immunoevasive anti-tumor adenovirus
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
DE69329877T2 (de) * 1992-05-07 2001-04-26 Affitech A/S, Oslo Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP2190863B1 (en) 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
ES2705714T3 (es) * 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
WO2010092963A1 (ja) * 2009-02-10 2010-08-19 国立大学法人 琉球大学 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
US20130316952A1 (en) 2013-11-28
BR112014029409A2 (https=) 2017-08-15
CA2874646C (en) 2020-12-01
JP2018171063A (ja) 2018-11-08
WO2013177398A2 (en) 2013-11-28
KR102053674B1 (ko) 2019-12-09
AU2017261625A1 (en) 2017-12-07
IL254652A0 (en) 2017-11-30
CA2874646A1 (en) 2013-11-28
US20160083436A1 (en) 2016-03-24
EA201590136A1 (ru) 2016-02-29
CN104470944A (zh) 2015-03-25
ES2670442T3 (es) 2018-05-30
IL235808A0 (en) 2015-01-29
HK1209134A1 (en) 2016-03-24
WO2013177398A3 (en) 2014-03-27
EA036487B1 (ru) 2020-11-16
DK2855509T3 (en) 2018-07-23
US9156887B2 (en) 2015-10-13
JP2021019595A (ja) 2021-02-18
AU2013266215B2 (en) 2017-12-07
EP2855509A2 (en) 2015-04-08
EP2855509A4 (en) 2016-01-13
JP2015519345A (ja) 2015-07-09
AU2017261625B2 (en) 2019-11-21
KR20150016585A (ko) 2015-02-12
PT2855509T (pt) 2018-08-03
JP7166081B2 (ja) 2022-11-07
IL254652B (en) 2019-12-31
US10280200B2 (en) 2019-05-07
US20180009854A1 (en) 2018-01-11
MX2014014384A (es) 2015-05-11
BR112014029409B1 (pt) 2022-11-29
EP2855509B1 (en) 2018-05-02
CN104470944B (zh) 2021-09-14
AU2013266215A1 (en) 2014-12-04
IL235808A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
AU2017261625B2 (en) Non-natural consensus albumin binding domains
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
DK3791896T5 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
AU2011328009A8 (en) Compounds and methods for treating pain
PH12013501636A1 (en) Treatment of osteoarthritis and pain
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
IL234023B (en) Compositions for treating amyotrophic lateral sclerosis
MX2015006973A (es) Inmunoterapia con agentes de enlace.
PH12014502274A1 (en) Anti-fcrn antibodies
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
PH12014502406B1 (en) Anti-il-23p19 antibodies
PL2888359T3 (pl) Białka fuzyjne i sposoby leczenia, zapobiegania lub łagodzenia bólu
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
EA201391171A1 (ru) Формы рифаксимина и их применение
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
NZ727446A (en) Therapeutic use of p75ntr neurotrophin binding protein
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu

Legal Events

Date Code Title Description
FG Grant or registration